These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37787097)

  • 1. Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial.
    Carbunaru S; Sun Z; McCall C; Ofori B; Marshall N; Wang H; Abern M; Liu L; Hollowell CMP; Sharifi R; Vidal P; Kajdacsy-Balla A; Sekosan M; Ferrer K; Wu S; Gallegos M; Gann PH; Moreira D; Sharp LK; Ferrans CE; Murphy AB
    Cancer Med; 2023 Oct; 12(19):19690-19700. PubMed ID: 37787097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
    Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
    Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions.
    Ramsey SD; Zeliadt SB; Fedorenko CR; Blough DK; Moinpour CM; Hall IJ; Smith JL; Ekwueme DU; Fairweather ME; Thompson IM; Keane TE; Penson DF
    World J Urol; 2011 Feb; 29(1):3-9. PubMed ID: 20959991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urologists' referral and radiation oncologists' treatment patterns regarding high-risk prostate cancer patients receiving radiotherapy within 6 months after radical prostatectomy: A prospective cohort analysis.
    Egger S; Smith DP; Brown BB; Kneebone AB; Dominello A; Brooks AJ; Young J; Xhilaga M; Haines M; O'Connell DL
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):134-143. PubMed ID: 31793211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
    J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial.
    Peabody JW; DeMaria LM; Tamondong-Lachica D; Florentino J; Czarina Acelajado M; Ouenes O; Richie JP; Burgon T
    BMC Urol; 2017 Jul; 17(1):51. PubMed ID: 28673277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy.
    Covas Moschovas M; Chew C; Bhat S; Sandri M; Rogers T; Dell'Oglio P; Roof S; Reddy S; Sighinolfi MC; Rocco B; Patel V
    Eur Urol Focus; 2022 Mar; 8(2):418-424. PubMed ID: 33757735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of a Biopsy Based 17-Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance.
    Badani KK; Kemeter MJ; Febbo PG; Lawrence HJ; Denes BS; Rothney MP; Rothberg MB; Brown GA
    Urol Pract; 2015 Jul; 2(4):181-189. PubMed ID: 37559258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urologists' Perceptions of Active Surveillance and Their Recommendations for Low-risk Prostate Cancer Patients.
    Xu J; Bock C; Janisse J; Schwartz KL; Triest J; Cher ML; Goodman M
    Urology; 2021 Sep; 155():83-90. PubMed ID: 33482128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge, attitudes and beliefs towards management of men with locally advanced prostate cancer following radical prostatectomy: an Australian survey of urologists.
    Brown B; Young J; Kneebone AB; Brooks AJ; Dominello A; Haines M
    BJU Int; 2016 Apr; 117 Suppl 4():35-44. PubMed ID: 25585989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 17-Gene Genomic Prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized Prostate Cancer.
    Janes JL; Boyer MJ; Bennett JP; Thomas VM; De Hoedt AM; Edwards V DK; Singla PK; Abran JM; Aboushwareb T; Salama JK; Freedland SJ
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):120-131. PubMed ID: 36306979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urologists' and GPs' knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands.
    Cremers R; van Asperen C; Kil P; Vasen H; Wiersma T; van Oort I; Kiemeney L
    Fam Cancer; 2012 Jun; 11(2):195-200. PubMed ID: 22160565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of Canadian urologists' opinions and prescribing patterns of testosterone replacement therapy in men on active surveillance for low-risk prostate cancer.
    Millar AC; Elterman DS; Goldenberg L; Van Asseldonk B; Curtis A; Jarvi K
    Can Urol Assoc J; 2016; 10(5-6):181-184. PubMed ID: 27713795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.
    Murphy AB; Abern MR; Liu L; Wang H; Hollowell CMP; Sharifi R; Vidal P; Kajdacsy-Balla A; Sekosan M; Ferrer K; Wu S; Gallegos M; King-Lee P; Sharp LK; Ferrans CE; Gann PH
    J Clin Oncol; 2021 May; 39(15):1660-1670. PubMed ID: 33835822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer.
    Helfand BT; Paterakos M; Wang CH; Talaty P; Abran J; Bennett J; Hall DW; Lehman A; Aboushwareb T
    PLoS One; 2022; 17(9):e0273782. PubMed ID: 36048818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study.
    Michalopoulos SN; Kella N; Payne R; Yohannes P; Singh A; Hettinger C; Yousefi K; Hornberger J;
    Curr Med Res Opin; 2014 Aug; 30(8):1547-56. PubMed ID: 24803160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of erectile dysfunction after radical prostatectomy. Urologists' assessment vs patient survey responses].
    Herkommer K; Niespodziany S; Zorn C; Gschwend JE; Volkmer BG
    Urologe A; 2006 Mar; 45(3):336, 338-42. PubMed ID: 16341512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.